Mouse Monoclonal CPV-VP2 Antibody

The CPV-VP2 antibody targets the VP2 capsid protein of Canine Parvovirus (CPV), a highly contagious pathogen causing severe gastrointestinal disease in dogs, particularly puppies. VP2. the major structural protein of CPV, forms the viral capsid and plays a critical role in host cell receptor binding, viral entry, and immune evasion. It is the primary antigenic determinant, eliciting neutralizing antibodies that are essential for protective immunity. CPV-VP2 antibodies are widely used in diagnostic assays (e.g., ELISA, immunohistochemistry) to detect viral antigens in clinical samples, aiding rapid diagnosis. They also serve as key tools in research to study viral pathogenesis, antigenic variation, and vaccine development. VP2’s genetic stability makes it a reliable target, though minor mutations in VP2 (e.g., in CPV-2a, 2b, 2c variants) influence host range and vaccine efficacy. Monoclonal antibodies against VP2 are explored for therapeutic use, offering passive immunity in high-risk cases. Overall, VP2-specific antibodies are vital for understanding CPV biology, improving diagnostics, and advancing preventive and therapeutic strategies against this globally significant veterinary pathogen.